$1.09
0.065.83%
Last update: Nov 10, 8:28 AM
Gain Therapeutics Inc
GANXNASDAQ
Gain Therapeutics fell 56.2% from $2.49 to $1.09, behind the S&P 500's +10.5%. Its worst day was Dec 18 (−44.4%), and its low came Nov 5 at $0.96.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-0.15 beat the $-0.15 estimate on $0.00 revenue.
+10.1% · S&P 500 +0.1%
Gain Therapeutics closed at its highest level of the year, 67.9% above where the year started.
Story events cover the past 12 months · Times ET
+3.2% · S&P 500 +0.7%
Gain Therapeutics shares fell 44.4%, while the S&P 500 rose 0.5%.
−44.4%, the year's worst day · S&P 500 +0.5%
Gain Therapeutics shares rose 31.1%, while the S&P 500 rose 0.7%.
+31.1%, the year's best day · S&P 500 +0.7%
Gain Therapeutics shares rose 21.5%, while the S&P 500 fell 1.3%.
+21.5% · S&P 500 −1.3%
Gain Therapeutics shares fell 25.6%, while the S&P 500 fell 1.4%.
−25.6% · S&P 500 −1.4%
EPS of $-0.11 beat the $-0.14 estimate on $0.00 revenue.
−3.6% · S&P 500 −1.8%
EPS of $-0.13 beat the $-0.14 estimate on $0.00 revenue.
0.0% · S&P 500 +0.2%
EPS of $-0.11 beat the $-0.15 estimate on $0.00 revenue.
+16.4% · S&P 500 −0.3%
Where it ended: a close of $1.09 on Nov 9, 2026. Up next: Q3 2026 earnings on Nov 10, 2026 (EPS est. $-0.13).
Nothing in the past 12 months.
All GANX analyst actionsNothing in the past 12 months.
All GANX dividend historyReplay the year: the line draws itself and stops at each of the 9 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for GANX and SPY from Benzinga historical bars. Not investment advice.
